Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - AU
$ 0.4931
-5.19 %
$ 13.6 M
Market Cap
-0.35
P/E
1. INTRINSIC VALUE
Balance Sheet
Incannex Healthcare Limited
| Current Assets | 16.2 M |
| Cash & Short-Term Investments | 5.86 M |
| Receivables | 0 |
| Other Current Assets | 10.3 M |
| Non-Current Assets | 845 K |
| Long-Term Investments | 0 |
| PP&E | 845 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 5.62 M |
| Accounts Payable | 527 K |
| Short-Term Debt | 163 K |
| Other Current Liabilities | 4.93 M |
| Non-Current Liabilities | 210 K |
| Long-Term Debt | 210 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Incannex Healthcare Limited
| Revenue | 12 K |
| Cost Of Revenue | 0 |
| Gross Profit | 12 K |
| Operating Expenses | 30.1 M |
| Operating Income | -30 M |
| Other Expenses | -11.6 M |
| Net Income | -18.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Incannex Healthcare Limited
| Net Income | -18.5 M |
| Depreciation & Amortization | 103 K |
| Capital Expenditures | -277 K |
| Stock-Based Compensation | 8.93 M |
| Change in Working Capital | -9.47 M |
| Others | -6.42 M |
| Free Cash Flow | -16.1 M |
Wall Street Analysts Price Targets
Incannex Healthcare Limited
IXHL has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
IXHL does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Incannex Healthcare Limited
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new oral combination medicines, today announced that the Company has completed Phase 2 patient enrollment in the global Phase 2/3 RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality.
globenewswire.com
- 2 weeks ago
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase 3 study. Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase 3 study.
globenewswire.com
- 1 month ago
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025
Dallas, Texas--(Newsfile Corp. - February 18, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the second quarter of fiscal year 2025, Incannex Healthcare Inc. reported R&D costs of $1.4M, a decrease from $2.6M in the same period of the previous year.
newsfilecorp.com
- 2 months ago
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended December 31, 2024.
globenewswire.com
- 2 months ago
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board
Dr. Wimms brings extensive industry and clinical development experience in sleep medicine innovation Dr. Wimms brings extensive industry and clinical development experience in sleep medicine innovation
globenewswire.com
- 2 months ago
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea
NEW YORK and MELBOURNE, Australia, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced positive topline results from a completed pharmacokinetics (PK) and safety study of IHL-42X, a novel, oral fixed-dose combination of acetazolamide and dronabinol for the treatment of Obstructive Sleep Apnea (OSA).
globenewswire.com
- 2 months ago
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025
Dallas, Texas--(Newsfile Corp. - December 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During 1Q 2025 the Company reported research and development costs of $2.9M, an increase of $0.3M from 1Q24.
newsfilecorp.com
- 4 months ago
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates
NEW YORK and MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today reported fiscal first quarter financial results and provided business highlights for the quarter ended September 30, 2024.
globenewswire.com
- 5 months ago
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer (CMO) effective immediately. Dr. Barbato's drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals, AbbVie, Biogen, Novartis, and Solvay. He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.
globenewswire.com
- 5 months ago
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Advancing proprietary, synthetic first and best-in-class cannabinoid and psychedelic-assisted therapeutics Conducting FDA phase 2/3 trial, IHL-42X, for the treatment of Obstructive Sleep Apnea (OSA) IHL-42X pivotal phase 2 top-line data expected first half 2025 Click image above to view full announcement.
newsfilecorp.com
- 6 months ago
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
NEW YORK and MELBOURNE, Australia, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious chronic diseases and significant unmet medical needs, today reported fiscal full year financial results and provided business updates.
globenewswire.com
- 6 months ago
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed pill-form treatment.
newsfilecorp.com
- 7 months ago
8. Profile
Summary
Incannex Healthcare Limited IXHL
COUNTRY
AU
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 13.6 M
Dividend Yield
0.00%
Description
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Contact
207/11 Solent Circuit, Sydney, NSW, 2153
https://www.incannex.com.au
IPO
Date
March 2, 2022
Employees
9
Officers
Mr. Joseph Swan
Chief Financial Officer, Treasurer & Secretary
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.
Chief Executive Officer of IncannexTM
Dr. Luigi M. Barbato M.D.
Chief Medical Officer
Natalie May
Head of Clinical Operations
Mr. Joel Bradley Latham
President, Chief Executive Officer & Executive Director
Mr. Lekhram Changoer M.Sc.
Chief Technology Officer & Member of Advisory Board
Dr. Mark Bleackley Ph.D.
Chief Scientific Officer, Head of Programs & Member of the Advisory Board